Patents by Inventor Julie Chao

Julie Chao has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12239884
    Abstract: The present disclosure generally relates to sharing workout content on electronic devices.
    Type: Grant
    Filed: September 23, 2022
    Date of Patent: March 4, 2025
    Assignee: Apple Inc.
    Inventors: Anthony D'Auria, Julie A. Arney, Jae Woo Chang, Edward Chao, Nathan De Vries, Michael D. Ford, Irene Suah Lee
  • Publication number: 20250032886
    Abstract: The present disclosure generally relates to user interfaces for managing, modifying, and/or outputting workout content.
    Type: Application
    Filed: October 15, 2024
    Publication date: January 30, 2025
    Inventors: Edward CHAO, Julie A. ARNEY, Jay K. BLAHNIK, Christopher P. FOSS, Paul T. NIXON, Pani PAGE
  • Patent number: 6864093
    Abstract: Prostasin protein has been found to be a useful marker for determination of the invasiveness of and as a means to treat human carcinomas. Using RT-PCR and western blot analyses, prostasin protein and mRNA expression were found in normal human prostate epithelial cells and the human prostate cancer cell line LNCaP, but not in the highly invasive human prostate cancer cell lines DU-145 and PC-3. Imunohistochemistry studies of human prostate cancer specimens revealed a down-regulation of prostasin in high-grade tumors. Using RT-PCR and western blot analyses, prostasin protein and mRNA expression were found in a non-invasive human breast cancer cell line, MCF-7, while invasive human breast cancer cell lines MDA-MB-231 and MDA-MB-435s were found not to express either the prostasin protein or the mRNA. A non-invasive human breast cancer cell line, MDA-MB-453, was shown to express prostasin mRNA but not prostasin protein.
    Type: Grant
    Filed: September 5, 2002
    Date of Patent: March 8, 2005
    Assignee: University of Central Florida
    Inventors: Karl X. Chai, Li-Mei Chen, Lee Chao, Julie Chao
  • Patent number: 6747140
    Abstract: The present invention provides a method of identifying a human subject as having an increased likelihood of regulating blood pressure with dietary sodium intake, comprising determining the presence in the subject of a tissue kallikrein promoter allele genotype correlated with an increased likelihood of regulating blood pressure with dietary sodium intake, whereby the presence of the genotype identifies the subject as having an increased likelihood of regulating blood pressure by dietary sodium intake.
    Type: Grant
    Filed: January 29, 2002
    Date of Patent: June 8, 2004
    Assignee: Medical University of South Carolina
    Inventors: Lee Chao, Julie Chao, Qing Song
  • Patent number: 6706483
    Abstract: Prostasin protein has been found to be a useful marker for determination of the invasiveness of and as a means to treat human carcinomas. Using RT-PCR and western blot analyses, prostasin protein and mRNA expression were found in normal human prostate epithelial cells and the human prostate cancer cell line LNCaP, but not in the highly invasive human prostate cancer cell lines DU-145 and PC-3. Imunohistochemistry studies of human prostate cancer specimens revealed a down-regulation of prostasin in high-grade tumors. Using RT-PCR and western blot analyses, prostasin protein and mRNA expression were found in a non-invasive human breast cancer cell line, MCF-7, while invasive human breast cancer cell lines MDA-MB-231 and MDA-MB-435s were found not to express either the prostasin protein or the mRNA. A non-invasive human breast cancer cell line. MDA-MB-453, was shown to express prostasin mRNA but not prostasin protein.
    Type: Grant
    Filed: February 18, 2003
    Date of Patent: March 16, 2004
    Assignee: University of Central Florida
    Inventors: Karl X. Chai, Li-Mei Chen, Lee Chao, Julie Chao
  • Patent number: 6689614
    Abstract: Prostasin protein has been found to be a useful marker for determination of the invasiveness of and as a means to treat human carcinomas. Using RT-PCR and western blot analyses, prostasin protein and mRNA expression were found in normal human prostate epithelial cells and the human prostate cancer cell line LNCaP, but not in the highly invasive human prostate cancer cell lines DU-145 and PC-3. Imunohistochemistry studies of human prostate cancer specimens revealed a down-regulation of prostasin in high-grade tumors. Using RT-PCR and western blot analyses, prostasin protein and mRNA expression were found in a non-invasive human breast cancer cell line, MCF-7, while invasive human breast cancer cell lines MDA-MB-231 and MDA-MB-435s were found not to express either the prostasin protein or the mRNA. A non-invasive human breast cancer cell line, MDA-MB-453, was shown to express prostasin mRNA but not prostasin protein.
    Type: Grant
    Filed: February 18, 2003
    Date of Patent: February 10, 2004
    Assignee: University of Central Florida
    Inventors: Karl X. Chai, Li-Mei Chen, Lee Chao, Julie Chao
  • Publication number: 20030157490
    Abstract: The present invention provides a method of identifying a human subject as having an increased likelihood of regulating blood pressure with dietary sodium intake, comprising determining the presence in the subject of a tissue kallikrein promoter allele genotype correlated with an increased likelihood of regulating blood pressure with dietary sodium intake, whereby the presence of the genotype identifies the subject as having an increased likelihood of regulating blood pressure by dietary sodium intake.
    Type: Application
    Filed: January 29, 2002
    Publication date: August 21, 2003
    Applicant: Medical University of South Carolina
    Inventors: Lee Chao, Julie Chao, Qing Song
  • Patent number: 6569684
    Abstract: Prostasin protein has been found to be a useful marker for determination of the invasiveness of and as a means to treat human carcinomas. Using RT-PCR and western blot analyses, prostasin protein and mRNA expression were found in normal human prostate epithelial cells and the human prostate cancer cell line LNCaP, but not in the highly invasive human prostate cancer cell lines DU-145 and PC-3. Imunohistochemistry studies of human prostate cancer specimens revealed a down-regulation of prostasin in high-grade tumors. Using RT-PCR and western blot analyses, prostasin protein and mRNA expression were found in a non-invasive human breast cancer cell line, MCF-7, while invasive human breast cancer cell lines MDA-MB-231 and MDA-MB-435s were found not to express either the prostasin protein or the mRNA. A non-invasive human breast cancer cell line, MDA-MB-453, was shown to express prostasin mRNA but not prostasin protein.
    Type: Grant
    Filed: January 5, 2001
    Date of Patent: May 27, 2003
    Assignee: University of Central Florida
    Inventors: Karl X. Chai, Li-Mei Chen, Lee Chao, Julie Chao
  • Patent number: 6376182
    Abstract: The present invention provides a method of identifying a human subject as having an increased likelihood of regulating blood pressure with dietary sodium intake, comprising determining the presence in the subject of a tissue kallikrein promoter allele genotype correlated with an increased likelihood of regulating blood pressure with dietary sodium intake, whereby the presence of the genotype identifies the subject as having an increased likelihood of regulating blood pressure by dietary sodium intake.
    Type: Grant
    Filed: January 31, 2000
    Date of Patent: April 23, 2002
    Assignee: Medical University of South Carolina
    Inventors: Lee Chao, Julie Chao, Qing Song
  • Publication number: 20020039753
    Abstract: Prostasin protein has been found to be a useful marker for determination of the invasiveness of and as a means to treat human carcinomas. Using RT-PCR and western blot analyses, prostasin protein and mRNA expression were found in normal human prostate epithelial cells and the human prostate cancer cell line LNCaP, but not in the highly invasive human prostate cancer cell lines DU- 145 and PC-3. Imunohistochemistry studies of human prostate cancer specimens revealed a down-regulation of prostasin in high-grade tumors. Using RT-PCR and western blot analyses, prostasin protein and mRNA expression were found in a non-invasive human breast cancer cell line, MCF-7, while invasive human breast cancer cell lines MDA-MB-231 and MDA-MB-435s were found not to express either the prostasin protein or the mRNA. A non-invasive human breast cancer cell line, MDA-MB-453, was shown to express prostasin mRNA but not prostasin protein.
    Type: Application
    Filed: January 5, 2001
    Publication date: April 4, 2002
    Inventors: Karl X. Chai, Li-Mei Chen, Lee Chao, Julie Chao
  • Patent number: 5948616
    Abstract: A method is provided for identifying a human subject as having an increased or decreased risk of developing essential hypertension, comprising determining the presence in the subject of an allele in the promoter region of the subject's tissue kallikrein gene correlated with an increased or decreased risk of developing essential hypertension, the presence of the allele identifying the subject as having an increased or decreased risk of developing essential hypertension.
    Type: Grant
    Filed: May 14, 1997
    Date of Patent: September 7, 1999
    Assignee: MUSC Foundation for Research Development
    Inventors: Lee Chao, Julie Chao